Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T14:16:52.967Z.
Calculation as of: 2026-10-06T14:16:52.967Z.
Quote observation: 2026-10-06T14:15:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8ce36116f6c4cf8d6fa5d70ec9ce1d9cbc86489a03ebd5e18b87b9f8ced35068
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$1.49B
EV/Sales Ratio
14.15x
TTM Avg
10.18x
3Y Avg
7.41x
5Y Avg
6.19x
Market Cap
$1.46B
EV/Sales Ratio
0.71x
TTM Avg
0.73x
3Y Avg
0.58x
5Y Avg
0.61x
Market Cap
$1.45B
EV/Sales Ratio
65.29x
TTM Avg
138.10x
3Y Avg
89.44x
5Y Avg
89.44x
Market Cap
$1.40B
EV/Sales Ratio
N/A
TTM Avg
781.47x
3Y Avg
902.36x
5Y Avg
638.00x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GH Research PLC (GHRS) | $1.49B | N/A | N/A | N/A | N/A |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.49B | 14.15x | 10.18x | 7.41x | 6.19x |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 0.71x | 0.73x | 0.58x | 0.61x |
| Certara, Inc. (CERT)vs › | $1.52B | 3.99x | 3.18x | 5.10x | 7.42x |
| Innoviva, Inc. (INVA)vs › | $1.53B | 2.78x | 3.82x | 4.31x | 4.24x |
| Braveheart Bio, Inc. (BRVE)vs › | $1.45B | N/A | N/A | N/A | N/A |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.45B | 65.29x | 138.10x | 89.44x | 89.44x |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 6.54x | 6.81x | 12.09x | 18.83x |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.40B | N/A | 781.47x | 902.36x | 638.00x |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.35B | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
